Knowledge and confidence gaps in differentiating PARP inhibitors among community oncology providers.

Abstract

Listen

Translate article

e21002 Background: Data and professional recommendations regarding the use of Poly(ADP-ribose) polymerase inhibitors (PARPis) for patients with ovarian cancer have evolved rapidly, challenging providers who manage patients with ovarian cancer (OC). Coupling confidence-based learning with continuing education (CE) is a proven tool to address such challenges towards enhanced patient care. Methods: A confidence-based continuing education (CE) activity was developed to address the evolving landscape of PARPi use in patients with OC. Pre-, intra-, and post-test assessment was used to quantify baseline parameters as well as the impact of education on knowledge and behaviors. The CME activity was available for credit from October 31, 2022 to October 30, 2023. Results: In total, 354 community oncology physicians or advanced practice providers (APPs) who see an average of 6 patients with OC per month completed the education. Baseline knowledge and confidence was low on topics related to strategies for molecular testing (29% correct) as well as the use of PARPis (27% correct). Moreover, on average, only 3% of those who answered correctly were confident in their response, highlighting a lack of confidence even in those who were correct. These knowledge and confidence gaps translated to only 24% of providers who use appropriate testing to determine BRCA1/2 and HRD status and only 16% feeling comfortable in differentiating PARPis. Additionally, while providers showed slight preference for olaparib in patients with homologous recombination deficiency (HRD) and niraparib in patients without HRD, on average 30% of providers were unsure of which agent to use in each clinical context. Overall, at baseline only 24% of providers reported individualizing the use of PARPis based on patient and tumor characteristics. Post-learning, there was a 46% increase in knowledge, and while the percentage of those who were confident and correct increased 21%, 76% remained unconfident. Still, these gains in knowledge and confidence resulted in two-thirds of providers making practice improvements in their use of PARPis, which resulted in improvements in patient health. Conclusions: The rapid evolution of the PARPi therapeutic landscape has caused gaps in knowledge, confidence, and behaviors. Ongoing and rapidly developed CE is a critical tool to address these challenges as data and recommendations for use continue to evolve rapidly.[Table: see text]